MOMENTA PHARMA THIRD-QUARTER LOSS WIDENS
Biotech drug developer Momenta Pharmaceuticals Inc. said Wednesday its third-quarter loss grew as the company increased spending. The company's loss widened to $6 million, or 21 cents per share, from $4.3 million, or 18 cents per share, a year ago. Revenue increased 60 percent to $3 million from $1.8 million. All the company's revenue comes from a licensing agreement with an affiliate of Novartis AG.